TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00713193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: 2-3 mg/kg orally in a twice day divided dose for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 1 mg/kg orally, daily for at least 30 days, then tapered over 30 days after achieving remission.
Study: NCT03660345

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PPV/MP
Description: 23 gauge Pars Plana Vitrectomy with Internal Limiting Membrane Peeling
Study: NCT06080204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide LAR
Description: Octreotide LAR (Sandostatin® LAR, Novartis Pharmaceuticals Corporation) treatment by deep intramuscular injection at a dose of 30 mg every 28 days for 6-12 months。
Study: NCT00322218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zevalin
Description: Zevalin study treatment regimen consisted of 2 rituximab i.v. infusions (Day 1 and Day 7-9) and one \[90Y\]-ibritumomab tiuxetan infusion in connection with the second rituximab infusion.~The core treatment regimen in the Zevalin arm was:~Day 1: Rituximab i.v. infusion 250 mg/m\^2~Day 7-to 9: Rituximab i.v. infusion 250 mg/m\^2 immediately followed by \[90Y\]-ibritumomab tiuxetan 14.8 MBq/kg (0.4 mCi/kg) with a maximum dose of 1184 MBq (32 mCi),administered as slow intravenous push over 10 minutes.
Study: NCT02458118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secretin
Description: Secretin 1 IU/kg over 3 min
Study: NCT01143636

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Chronic pain subjects will be randomized to receive either active or sham stimulation for the duration of the trial. The subject will receive 10 consecutive sessions at an intensity of 2mA with each session lasting 20 minutes. If the subject receives active stimulation the current will be applied for the full 20 minutes, while in the sham group current will only be applied for 30 seconds. In the healthy cohort, subjects will receive one session of active stimulation and one session of sham stimulation. The parameters will be the same as the pain subjects, at an intensity of 2mA for 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Chronic pain subjects will be randomized to receive either active or sham stimulation for the duration of the trial. The subject will receive 10 consecutive sessions at an intensity of 2mA with each session lasting 20 minutes. If the subject receives active stimulation the current will be applied for the full 20 minutes, while in the sham group current will only be applied for 30 seconds. In the healthy cohort, subjects will receive one session of active stimulation and one session of sham stimulation. The parameters will be the same as the pain subjects, at an intensity of 2mA for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Chronic pain subjects will be randomized to receive either active or sham stimulation for the duration of the trial. The subject will receive 10 consecutive sessions at an intensity of 2mA with each session lasting 20 minutes. If the subject receives active stimulation the current will be applied for the full 20 minutes, while in the sham group current will only be applied for 30 seconds. In the healthy cohort, subjects will receive one session of active stimulation and one session of sham stimulation. The parameters will be the same as the pain subjects, at an intensity of 2mA for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Chronic pain subjects will be randomized to receive either active or sham stimulation for the duration of the trial. The subject will receive 10 consecutive sessions at an intensity of 2mA with each session lasting 20 minutes. If the subject receives active stimulation the current will be applied for the full 20 minutes, while in the sham group current will only be applied for 30 seconds. In the healthy cohort, subjects will receive one session of active stimulation and one session of sham stimulation. The parameters will be the same as the pain subjects, at an intensity of 2mA for 20 minutes.
Study: NCT03290677

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: This involves passing a special needle into the body (cryoprobe) to freeze tumor and kill a small part (not all) of the cancer. The immune system will respond to the damage caused by freezing part of the tumor.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Removing a small piece of the affected area to confirm cancer
Study: NCT04463355

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video discharge instructions
Description: Short video (2 minutes) including information about clinical features, management and follow up of pediatric patients with acute gastroenteritis
Study: NCT03660345

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal injection
Description: Intravitreal ziv-Aflibercept
Study: NCT00351988

Intervention type: BEHAVIORAL
Intervention: Phenomenological Interviews
Description: Part 1 will collect phenomenologic data to understand the meaning of caregiver burden, and the positive experiences faced when caring for a underserved patient with advanced lung cancer.

Intervention type: BEHAVIORAL
Intervention: Phenomenological Interviews
Description: Part 1 will collect phenomenologic data to understand the meaning of caregiver burden, and the positive experiences faced when caring for a underserved patient with advanced lung cancer.
Study: NCT01103817

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Dosing If the 25 OH Vitamin D level at Baseline/Screening is less than 20 nmol/L then the subject will receive 2000 IU daily.~If the 25 OH Vitamin D level at Baseline/Screening is between 20 and 37.5 nmol/L then the subject will receive 1000 IU daily.
Study: NCT00351988

Intervention type: BEHAVIORAL
Intervention: Phenomenological Interviews
Description: Part 1 will collect phenomenologic data to understand the meaning of caregiver burden, and the positive experiences faced when caring for a underserved patient with advanced lung cancer.

Intervention type: BEHAVIORAL
Intervention: Quantitative Interviews
Description: Part 2 will collect quantitative data to determine the prevalence and severity of symptoms experienced by caregivers and their contribution to caregiver burden.

Intervention type: BEHAVIORAL
Intervention: Quantitative Interviews
Description: Part 2 will collect quantitative data to determine the prevalence and severity of symptoms experienced by caregivers and their contribution to caregiver burden.

Intervention type: BEHAVIORAL
Intervention: Quantitative Interviews
Description: Part 2 will collect quantitative data to determine the prevalence and severity of symptoms experienced by caregivers and their contribution to caregiver burden.
Study: NCT04585347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALZ-801 170 mg Fasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALZ-801 205 mg Fasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALZ-801 205 mg After Food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALZ-801 342 mg Fasting
Study: NCT02990637

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: OLECOL
Description: Olive leaf extract

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study: NCT06021574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VDJ001
Description: a novel recombinant humanized anti-interleukin-6 receptor monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VDJ001
Description: a novel recombinant humanized anti-interleukin-6 receptor monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VDJ001
Description: a novel recombinant humanized anti-interleukin-6 receptor monoclonal antibody
Study: NCT01607008

Intervention type: OTHER
Group type: OTHER
Intervention: MRI imaging
Description: 3 total MRI imaging studies:~1. pre standard radiation treatment~2. during standard radiation treatment~3. post standard radiation treatment
Study: NCT05111704

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Body Tape
Description: The intervention group received a three-week treatment with Balance Body Tape (BBT) (product by Babota AB), the control group received no treatment. A questionnaire regarding pain, including a Numeric Rating Scale (NRS) measuring pain intensity, and a Photographic posture analysis measurement (PPAM) of habitual sitting posture were accomplished before and after the intervention for both groups.
Study: NCT03634644

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 fatty acid
Description: Omega 3 fatty acid,mainly composed of EPA and DHA.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: mainly composed of corn oil
Study: NCT06021574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VDJ001
Description: a novel recombinant humanized anti-interleukin-6 receptor monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT03401593

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam with fentanyl
Description: Radio-frequency catheter ablation is performed in the post-absorptive state after sedation with midazolam and fentanyl. Multipolar catheters were positioned in the coronary sinus, His, and the right atrium. The three-dimensional LA geometry was reconstructed using a CARTO or NavX electroanatomical mapping system. Circumferential pulmonary vein isolation was performed in all patients using a irrigated-tip catheter. A circular mapping catheter was used to confirm the isolation of the pulmonary veins. Successful ablation was defined by the elimination of all the pulmonary vein potentials along the antrum or inside the veins. If the AF was not terminated after elimination of all the pulmonary vein potentials, linear ablation and complex fragmented atrial electrogram ablation were performed.
Study: NCT03645928

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lifileucel
Description: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with Lifileucel followed by IL-2 administration. Lifileucel will be administered to patients once (on Day 0) during the study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lifileucel
Description: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with Lifileucel followed by IL-2 administration. Lifileucel will be administered to patients once (on Day 0) during the study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LN-145
Description: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration. TIL will be administered to patients once (on Day 0) during the study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LN-145
Description: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration. TIL will be administered to patients once (on Day 0) during the study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LN-145
Description: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration. TIL will be administered to patients once (on Day 0) during the study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LN-145
Description: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration. TIL will be administered to patients once (on Day 0) during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Humanized antibody.~Pembrolizumab will be administered following tumor resection and will continue every 3 weeks or every 6 weeks thereafter for up to 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Humanized antibody.~Pembrolizumab will be administered following tumor resection and will continue every 3 weeks or every 6 weeks thereafter for up to 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Humanized antibody.~Pembrolizumab will be administered following tumor resection and will continue every 3 weeks or every 6 weeks thereafter for up to 2 years.
Study: NCT06021574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT03645928

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LN-145-S1
Description: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145-S1) followed by IL-2 administration. TIL will be administered to patients once (on Day 0) during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Monoclonal antibody~Ipilimumab will be administered as a single dose prior to tumor resection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Monoclonal antibody~Nivolumab will be administered once prior to tumor resection. The second dose will be administered prior to TIL administration and dosing will continue every 4 weeks for up to 2 years.
Study: NCT04348110

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: consume 2 tablets per day for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberry Chewable Tablets
Description: consume 2 tablets per day for 8 weeks
Study: NCT01161732

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early surgery
Description: Early surgery is performed within 2 months of randomization.
Study: NCT04336358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Telemedicine consultation online
Study: NCT04297059

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ajyal Salima
Description: It comprises in class-activities, meetings with parents and improvement of school foodservice
Study: NCT03138304

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video game
Description: Night Shift is an adventure video game with the transformational goal of teaching physicians key characteristics of patients with non-representative severe injuries - injuries classified by the American College of Surgeons as life-threatening or critical but that do not fit the archetype of injuries typically requiring treatment at a trauma center.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational program
Description: Two commercially available applications designed to teach physicians the trauma triage guidelines disseminated by the American College of Surgeons.
Study: NCT03081468

Intervention type: DEVICE
Intervention: Binocular OCT prototype
Description: Participants in the study will undergo pupil measurement using a prototype binocular OCT imaging system (Envision Diagnostics, Inc., CA). For the binocular OCT imaging system, testing will be performed twice in the same session, by the same examiner, to allow assessment of repeatability (test-retest variability).

Intervention type: DEVICE
Intervention: Binocular OCT prototype
Description: Participants in the study will undergo pupil measurement using a prototype binocular OCT imaging system (Envision Diagnostics, Inc., CA). For the binocular OCT imaging system, testing will be performed twice in the same session, by the same examiner, to allow assessment of repeatability (test-retest variability).
Study: NCT04667962

Intervention type: OTHER
Intervention: Online questionnaire
Description: Participants will have to complete 3 online self-questionnaires: the first one at enrollment, the second one 1 month after enrollment (M1) and the third one 3 months after enrollment (M3). Each questionnaire will take an estimated 20 minutes to complete.
Study: NCT03081468

Intervention type: DEVICE
Intervention: Konan RAPDx
Description: Participants in the study will undergo pupil measurement using a validated, commercially available pupilometer (RAPDx; Konan Medical USA, Inc., Irvine, CA).

Intervention type: DEVICE
Intervention: Konan RAPDx
Description: Participants in the study will undergo pupil measurement using a validated, commercially available pupilometer (RAPDx; Konan Medical USA, Inc., Irvine, CA).
Study: NCT03036904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered orally on days 3-12 in cycle 1, and days 1-10 with all subsequent cycles except dose level -1. If dose level -1 is required, venetoclax will be administered on days 3-7 in cycle 1 and 1-5 with subsequent cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered as an IV infusion at 375 mg/m2 on day 1 of each cycle of DA-EPOCH-R, immediately prior to the start of chemotherapy. Oral pre-medication 650 mg of acetaminophen and 50-100 mg diphenhydramine hydrochloride will be administered 30 to 60 minutes prior to starting each infusion of rituximab. The first rituximab infusion should be started at 50 mg/hr, and increased in 50-mg/hr increments every 30 minutes to a maximum rate of 400 mg/hr. If this rate of escalation is well tolerated the second and subsequent infusions can begin at a rate of 100 mg/hr and increase in 100 mg/hr increments every 30 minutes to a maximum of 400 mg/hr. CAUTION: DO NOT ADMINISTER AS AN INTRAVENOUS PUSH OR BOLUS.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
Study: NCT03036904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Vincristine Sulfate will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. Prednisone will be given orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Doxorubicin Hydrochloride will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
Study: NCT03671980

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: My Medical record website
Description: Website comprising patient records, blood and other test results, useful information on IBD, and messaging service to communicate with IBD team, plus home smartphone faecal calprotectin monitoring.
Study: NCT00497315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination chemotherapy (pemetrexed + cisplatin)
Description: pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 (q 3 weeks for 3 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination chemotherapy (pemetrexed + cisplatin)
Description: pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 (q 3 weeks for 3 cycles)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: thoracic irradiation + pemetrexed
Description: pemetrexed 500 mg/m2 (q 3weeks for 2 cycles), 60 GY (30 fractions of 2 GY)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: thoracic irradiation + pemetrexed
Description: pemetrexed 500 mg/m2 (q 3weeks for 2 cycles), 60 GY (30 fractions of 2 GY)
Study: NCT02595138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Study: NCT01792271

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled 7% HS (NaCl) home treatment
Description: Administering inhaled 7% NaCl for two weeks of home treatment vs. a placebo of 0.12% NaCL during a separate home treatment period, and assessing the effects of each primarily by MCC study.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled 7% HS (NaCl) home treatment
Description: Administering inhaled 7% NaCl for two weeks of home treatment vs. a placebo of 0.12% NaCL during a separate home treatment period, and assessing the effects of each primarily by MCC study.
Study: NCT02337270

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5Ag85A
Description: Aerosol administration of Ad5Ag85A
Study: NCT01231373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polidocanol injectable foam, 1.0%
Description: 1.0% polidocanol foam injection
Study: NCT02337270

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5Ag85A
Description: Aerosol administration of Ad5Ag85A

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5Ag85A
Description: Aerosol administration of Ad5Ag85A
Study: NCT00734123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin or Atorvastatin
Description: Simvastatin 10-40 mg or Atorvastatin 20-40 mg will be prescribed according to LDL cholesterol reduction target.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril
Description: Enalapril 10 mg/day will be prescribed as the initial treatment. Doses and adding drugs will be titrated accordingly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin or clopidogrel
Description: Aspirin 100 mg or clopidogrel 75 mg/ per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimonabant
Description: In both arms, we will follow the standard clinical care in terms of treatments, as far as obesity and diabetes mellitus is concerned.~Drugs will be prescribed as the standard clinical care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rimonabant
Description: In both arms, we will follow the standard clinical care in terms of treatments, as far as obesity and diabetes mellitus is concerned.~Drugs will be prescribed as the standard clinical care